Finance

Lists
Q3 2026 earnings • released • EPS beat +35.29% • Revenue beat +0.95%
See results
ZVRA:NASDAQ
Zevra Therapeutics Inc
$11.59
+10.07%
(+1.06) 1D
$11.45
-1.21% (-0.14)
After hours
Closed: Nov 6, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZVRA...
Open
$10.59
High
$11.63
Low
$10.44
Mkt. cap
689.66M
Avg. vol.
905.94K
Volume
1.53M
P/E ratio
9.06
52-wk high
$15.04
52-wk low
$8.01
EPS
$1.28
Beta
1.01
Shares outstanding
59.50M
No. of employees
61
Open
$10.59
High
$11.63
Low
$10.44
Mkt. cap
689.66M
Avg. vol.
905.94K
Volume
1.53M
P/E ratio
9.06
52-wk high
$15.04
52-wk low
$8.01
EPS
$1.28
Beta
1.01
Shares outstanding
59.50M
No. of employees
61
News stories
From web sources and news partners
About Zevra Therapeutics Inc
CEO-
Employees61
Founded2006
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitezevra.com
Analyst ratings
Based on 7 analysts giving stock ratings to ZVRA in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ZVRA in the last 3 months.
Highest
Current $11.59
$35.00 (+201.98%)
Average
$25.50 (+120.02%)
Lowest
$20.00 (+72.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason McCarthy
Maxim Group
Buy
Maintained
$35.00
+202%
11/04/2026
Eddie Hickman
Guggenheim
Buy
Maintained
$23.00
+98.4%
11/04/2026
Kambiz Yazdi
BTIG
Buy
Maintained
$24.00
+107.1%
11/04/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Maintained
$20.00
+72.6%
11/03/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$25.00
+115.7%
11/03/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$26.00
+124.3%
11/04/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
09/30/2026
Jonathan Aschoff
Roth MKM
Buy
Maintained
$21.00
+81.2%
08/06/2026
Jason Butler
Citizens JMP
Buy
Maintained
$28.00
+141.6%
08/06/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/06/2026
Unknown Analyst
Roth MKM
Buy
Maintained
$21.00
+81.2%
05/07/2026
Last report
Nov 3, 2026
Fiscal period
Q3 2026
$0.23 / $0.17
+35.29%beat
Revenue / Est. (USD)
37.76M / 37.40M
+0.95%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
34.12M
36.22M
39.66M
37.76M
Cost of goods sold
1.52M
1.90M
1.52M
1.79M
Cost of revenue
1.52M
1.90M
1.52M
1.79M
Research and development expenses
2.52M
4.39M
4.49M
4.94M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
20.45M
20.78M
16.56M
19.13M
Operating expense
23.29M
25.49M
21.36M
24.38M
Total operating expenses
24.81M
27.39M
22.89M
26.18M
Operating income
9.32M
8.83M
16.78M
11.58M
Other non operating income
3.56M
-6.25M
-6.41M
5.14M
EBT including unusual items
12.67M
44.80M
12.79M
19.72M
EBT excluding unusual items
12.64M
4.46M
12.93M
19.76M
Income tax expense
501.00K
6.91M
4.04M
510.00K
Effective tax rate
3.96%
15.43%
31.59%
2.59%
Other operating expenses
-
-
-
-
Net income
12.16M
37.89M
8.75M
19.21M
Net profit margin
35.65%
104.61%
22.07%
50.87%
Earnings per share
0.19
0.18
0.25
0.23
Interest and investment income
1.71M
3.59M
2.56M
3.03M
Interest expense
-1.95M
-1.71M
-
-
Net interest expenses
-236.00K
1.88M
2.56M
3.03M
Depreciation and amortization charges
-
-
-
-
EBITDA
9.68M
9.20M
17.14M
11.96M
Gain or loss from assets sale
63.00K
-43.31M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps